11,492 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Purchased by Legacy Capital Group California Inc.

Legacy Capital Group California Inc. purchased a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,492 shares of the company's stock, valued at approximately $883,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC increased its stake in GeneDx by 346.3% during the third quarter. Barclays PLC now owns 18,921 shares of the company's stock worth $803,000 after acquiring an additional 14,681 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of GeneDx during the 3rd quarter worth about $325,000. Charles Schwab Investment Management Inc. raised its holdings in GeneDx by 304.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company's stock valued at $6,240,000 after buying an additional 110,666 shares during the period. Chartwell Investment Partners LLC purchased a new stake in GeneDx in the 3rd quarter valued at about $1,722,000. Finally, Lisanti Capital Growth LLC acquired a new position in GeneDx in the third quarter valued at about $1,554,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. TD Cowen boosted their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. Craig Hallum boosted their target price on GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Wells Fargo & Company lifted their price objective on GeneDx from $34.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their target price on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $72.33.

Remove Ads

Insider Activity at GeneDx

In related news, CEO Katherine Stueland sold 1,657 shares of the company's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.36. Following the completion of the sale, the chief executive officer now directly owns 3,937 shares of the company's stock, valued at $308,975.76. This represents a 29.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Feeley sold 1,137 shares of the firm's stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $76.37, for a total value of $86,832.69. Following the transaction, the chief financial officer now owns 24,731 shares in the company, valued at $1,888,706.47. This represents a 4.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 127,584 shares of company stock valued at $11,336,520 over the last three months. 27.30% of the stock is owned by corporate insiders.

GeneDx Stock Up 0.9 %

Shares of GeneDx stock traded up $0.85 on Tuesday, reaching $95.85. 1,387,958 shares of the company were exchanged, compared to its average volume of 1,254,293. The stock's 50 day moving average price is $79.34 and its 200-day moving average price is $63.80. The company has a market cap of $2.63 billion, a P/E ratio of -48.90 and a beta of 2.01. GeneDx Holdings Corp. has a 1-year low of $7.56 and a 1-year high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. As a group, equities analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.